The role of fulvestrant in endometrial cancer

Stefano Bogliolo, Chiara Cassani, Mattia Dominoni, Anna Orlandini, Simone Ferrero, Anna Daniela Iacobone, Franco Viazzo, Pierluigi Venturini, Arsenio Spinillo, Barbara Gardella

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Endometrial cancer is the most common malignancy of the female genital tract in industrialized countries. The traditional treatment of endometrial cancer is based on a surgical approach. In recent years, systemic endocrine therapy has demonstrated good efficacy in recurrent or metastatic setting, delaying progression, ameliorating quality of life and palliating symptoms. Areas covered: Phase I and II studies on selective estrogen receptor down-regulators used for the treatment of endometrial cancer treatment have been reviewed. The pharmacokinetic and pharmacodynamic features of selective receptor down-regulators have been also investigated. Expert opinion: Selective estrogen receptor down-regulators may exhibit clinical efficacy in the treatment of gynecological malignancies due to their pure estrogen receptor antagonist properties. However, up to now data are still limited and some unsolved questions remain. Fulvestrant has poor oral bioavailability and low pharmacodynamic characteristics. Further trials are required to examine new selective estrogen receptor down-regulator agents with better pharmacodynamic and pharmacokinetic profiles.

Original languageEnglish
JournalExpert Opinion on Drug Metabolism and Toxicology
DOIs
Publication statusE-pub ahead of print - Oct 4 2016

Fingerprint

Pharmacodynamics
Endometrial Neoplasms
Estrogen Receptors
Pharmacokinetics
Oncology
Expert Testimony
Developed Countries
Biological Availability
Neoplasms
Quality of Life
fulvestrant
Therapeutics

Keywords

  • Journal Article

Cite this

The role of fulvestrant in endometrial cancer. / Bogliolo, Stefano; Cassani, Chiara; Dominoni, Mattia; Orlandini, Anna; Ferrero, Simone; Iacobone, Anna Daniela; Viazzo, Franco; Venturini, Pierluigi; Spinillo, Arsenio; Gardella, Barbara.

In: Expert Opinion on Drug Metabolism and Toxicology, 04.10.2016.

Research output: Contribution to journalArticle

@article{b456c43244264bd7adcb671ff799cf5d,
title = "The role of fulvestrant in endometrial cancer",
abstract = "INTRODUCTION: Endometrial cancer is the most common malignancy of the female genital tract in industrialized countries. The traditional treatment of endometrial cancer is based on a surgical approach. In recent years, systemic endocrine therapy has demonstrated good efficacy in recurrent or metastatic setting, delaying progression, ameliorating quality of life and palliating symptoms. Areas covered: Phase I and II studies on selective estrogen receptor down-regulators used for the treatment of endometrial cancer treatment have been reviewed. The pharmacokinetic and pharmacodynamic features of selective receptor down-regulators have been also investigated. Expert opinion: Selective estrogen receptor down-regulators may exhibit clinical efficacy in the treatment of gynecological malignancies due to their pure estrogen receptor antagonist properties. However, up to now data are still limited and some unsolved questions remain. Fulvestrant has poor oral bioavailability and low pharmacodynamic characteristics. Further trials are required to examine new selective estrogen receptor down-regulator agents with better pharmacodynamic and pharmacokinetic profiles.",
keywords = "Journal Article",
author = "Stefano Bogliolo and Chiara Cassani and Mattia Dominoni and Anna Orlandini and Simone Ferrero and Iacobone, {Anna Daniela} and Franco Viazzo and Pierluigi Venturini and Arsenio Spinillo and Barbara Gardella",
year = "2016",
month = "10",
day = "4",
doi = "10.1080/17425255.2016.1244264",
language = "English",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - The role of fulvestrant in endometrial cancer

AU - Bogliolo, Stefano

AU - Cassani, Chiara

AU - Dominoni, Mattia

AU - Orlandini, Anna

AU - Ferrero, Simone

AU - Iacobone, Anna Daniela

AU - Viazzo, Franco

AU - Venturini, Pierluigi

AU - Spinillo, Arsenio

AU - Gardella, Barbara

PY - 2016/10/4

Y1 - 2016/10/4

N2 - INTRODUCTION: Endometrial cancer is the most common malignancy of the female genital tract in industrialized countries. The traditional treatment of endometrial cancer is based on a surgical approach. In recent years, systemic endocrine therapy has demonstrated good efficacy in recurrent or metastatic setting, delaying progression, ameliorating quality of life and palliating symptoms. Areas covered: Phase I and II studies on selective estrogen receptor down-regulators used for the treatment of endometrial cancer treatment have been reviewed. The pharmacokinetic and pharmacodynamic features of selective receptor down-regulators have been also investigated. Expert opinion: Selective estrogen receptor down-regulators may exhibit clinical efficacy in the treatment of gynecological malignancies due to their pure estrogen receptor antagonist properties. However, up to now data are still limited and some unsolved questions remain. Fulvestrant has poor oral bioavailability and low pharmacodynamic characteristics. Further trials are required to examine new selective estrogen receptor down-regulator agents with better pharmacodynamic and pharmacokinetic profiles.

AB - INTRODUCTION: Endometrial cancer is the most common malignancy of the female genital tract in industrialized countries. The traditional treatment of endometrial cancer is based on a surgical approach. In recent years, systemic endocrine therapy has demonstrated good efficacy in recurrent or metastatic setting, delaying progression, ameliorating quality of life and palliating symptoms. Areas covered: Phase I and II studies on selective estrogen receptor down-regulators used for the treatment of endometrial cancer treatment have been reviewed. The pharmacokinetic and pharmacodynamic features of selective receptor down-regulators have been also investigated. Expert opinion: Selective estrogen receptor down-regulators may exhibit clinical efficacy in the treatment of gynecological malignancies due to their pure estrogen receptor antagonist properties. However, up to now data are still limited and some unsolved questions remain. Fulvestrant has poor oral bioavailability and low pharmacodynamic characteristics. Further trials are required to examine new selective estrogen receptor down-regulator agents with better pharmacodynamic and pharmacokinetic profiles.

KW - Journal Article

U2 - 10.1080/17425255.2016.1244264

DO - 10.1080/17425255.2016.1244264

M3 - Article

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

ER -